Canlyniadau Chwilio - Ana Arance

Mireinio'r Canlyniadau
  1. 1
    Molecular Markers and Targets in Melanoma

    Molecular Markers and Targets in Melanoma gan Cristina Teixidó, Paola Castillo, Clara Martínez-Vila, Ana Arance, Lluçia Alós

    Cyhoeddwyd 2021
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  2. 2
    Vasculitic neuropathy induced by pembrolizumab

    Vasculitic neuropathy induced by pembrolizumab gan Francisco Aya, Virginia Ruíz-Esquide, Margarita Viladot, Carme Font, Sergio Prieto‐González, A. Prat, Ana Arance

    Cyhoeddwyd 2016
    Cael y testun llawn
    Carta
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  3. 3
    Detection of Circulating Tumor DNA in Liquid Biopsy: Current Techniques and Potential Applications in Melanoma

    Detection of Circulating Tumor DNA in Liquid Biopsy: Current Techniques and Potential Applications in Melanoma gan Clara Martínez-Vila, Cristina Teixidó, Francisco Aya, Roberto Martín, Azucena González-Navarro, Lluçia Alós, Natalia Castrejón de Anta, Ana Arance

    Cyhoeddwyd 2025
    Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  4. 4
    Encorafenib (Lgx818), an Oral Braf Inhibitor, in Patients (Pts) with Braf V600E Metastatic Colorectal Cancer (Mcrc): Results of Dose Expansion in an Open-Label, Phase 1 Study

    Encorafenib (Lgx818), an Oral Braf Inhibitor, in Patients (Pts) with Braf V600E Metastatic Colorectal Cancer (Mcrc): Results of Dose Expansion in an Open-Label, Phase 1 Study gan Carlos Gomez‐Roca, Jean‐Pierre Delord, Caroline Robert, Manuel Hidalgo, Roger von Moos, Ana Arance, Elena Élez, Daniela Michel, Abdelkader Seroutou, Tim Demuth, Josep Tabernero

    Cyhoeddwyd 2014
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  5. 5
    Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006

    Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006 gan Omid Hamid, Caroline Robert, Antoni Ribas, F. Stephen Hodi, Euan Walpole, Adil Daud, Ana Arance, Ewan Brown, Christoph Höeller, Laurent Mortier, Jacob Schachter, Jianmin Long, Scot Ebbinghaus, Nageatte Ibrahim, Marcus O. Butler

    Cyhoeddwyd 2018
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  6. 6
    Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy

    Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy gan Aleix Prat, Huihui Fan, Aranzazu Fernández-Martínez, Katherine A. Hoadley, Rossella Martinello, María Vidal, Margarita Viladot, Estela Pineda, Ana Arance, Montserrat Muñoz, Laia Paré, Maggie C.U. Cheang, Bárbara Adamo, Charles M. Perou

    Cyhoeddwyd 2015
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  7. 7
    Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600–mutant melanoma

    Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients w... gan Paolo A. Ascierto, Reinhard Dummer, Helen Gogas, Keith T. Flaherty, Ana Arance, Mario Mandalà, Gabriella Liszkay, Claus Garbe, Dirk Schadendorf, Ivana Krajsová, Ralf Gutzmer, Jan Willem B. de Groot, Carmen Loquai, Ashwin Gollerkeri, Michael D. Pickard, Caroline Robert

    Cyhoeddwyd 2020
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  8. 8
    Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial

    Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial gan Brett Hughes, Eva Muñoz‐Couselo, Laurent Mortier, Å. Bratland, Ralf Gutzmer, Osama Roshdy, René González Mendoza, Jacob Schachter, Ana Arance, Florent Grange, Nicolás Meyer, Abhishek Joshi, Salem Billan, P. Zhang, Burak Gümüşçü, Ramona F. Swaby, Jean‐Jacques Grob

    Cyhoeddwyd 2021
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  9. 9
    Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of <i>BRAF</i>-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial

    Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of <i>BRAF</i>-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial gan Paolo A. Ascierto, Reinhard Dummer, Helen Gogas, Ana Arance, Mario Mandalà, Gabriella Liszkay, Claus Garbe, Dirk Schadendorf, Ivana Krajsová, Ralf Gutzmer, Vanna Chiarion‐Sileni, Caroline Dutriaux, Jan Willem B. de Groot, Naoya Yamazaki, Carmen Loquai, Caroline Robert, Keith T. Flaherty

    Cyhoeddwyd 2023
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  10. 10
    Immune-Related Gene Expression Profiling After PD-1 Blockade in Non–Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma

    Immune-Related Gene Expression Profiling After PD-1 Blockade in Non–Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma gan Aleix Prat, Alejandro Navarro, Laia Paré, Noemı́ Reguart, Patricia Galván, Tomás Pascual, Alex Martínez‐Martí, Paolo Nucíforo, Laura Comerma, Lluçia Alós, Núria Pardo, S. Cedrés, Cheng Fan, Joel S. Parker, Lydia Gaba, Iván Victoria, Núria Viñolas, Ana Vivancos, Ana Arance, Enriqueta Felip

    Cyhoeddwyd 2017
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  11. 11
    Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study

    Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study gan Grant A. McArthur, Michele Maio, Ana Arance, Paul Nathan, Christian U. Blank, Marie‐Françoise Avril, Claus Garbe, Axel Hauschild, Dirk Schadendorf, Omid Hamid, Michael Fluck, Melissa S. Thebeau, Jacob Schachter, Richard Kefford, Marc C. Chamberlain, Martina Makrutzki, Susan Robson, René González, Kim Margolin

    Cyhoeddwyd 2016
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  12. 12
    Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study

    Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study gan Helen Gogas, Brigitte Dréno, James Larkin, Lev Demidov, Daniil Stroyakovskiy, Zeynep Eroglu, Pier Francesco Ferrucci, Jacopo Pigozzo, Piotr Rutkowski, Jacek Mackiewicz, Isabelle Rooney, Athina Voulgari, Sarah M. Troutman, Bethany Pitcher, Guo Yu, Y. Yan, Marília Germanos de Castro, S. Mulla, Keith T. Flaherty, Ana Arance

    Cyhoeddwyd 2020
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  13. 13
    COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With<i>BRAF</i>V600–Mutant Melanoma

    COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With<i>BRAF</i>V600–Mutant Melanoma... gan Reinhard Dummer, Keith T. Flaherty, Caroline Robert, Ana Arance, Jan Willem B. de Groot, Claus Garbe, Helen Gogas, Ralf Gutzmer, Ivana Krajsová, Gabriella Liszkay, Carmen Loquai, Mario Mandalà, Dirk Schadendorf, Naoya Yamazaki, Alessandra di Pietro, Jean Cantey-Kiser, Adrian Edwards, Paolo A. Ascierto

    Cyhoeddwyd 2022
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  14. 14
    Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management

    Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management gan Helen Gogas, Keith T. Flaherty, Reinhard Dummer, Paolo A. Ascierto, Ana Arance, Mario Mandalà, Gabriella Liszkay, Claus Garbe, Dirk Schadendorf, Ivana Krajsová, Ralf Gutzmer, Vanna Chiarion‐Sileni, Caroline Dutriaux, Jan Willem B. de Groot, Naoya Yamazaki, Carmen Loquai, Ashwin Gollerkeri, Michael D. Pickard, Caroline Robert

    Cyhoeddwyd 2019
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  15. 15
    1036O Relatlimab (RELA) + nivolumab (NIVO) vs. NIVO in previously untreated metastatic or unresectable melanoma: Additional efficacy in RELATIVITY-047

    1036O Relatlimab (RELA) + nivolumab (NIVO) vs. NIVO in previously untreated metastatic or unresectable melanoma: Additional efficacy in RELATIVITY-047 gan F. Stephen Hodi, Hussein A. Tawbi, Evan J. Lipson, Dirk Schadendorf, P.A. Ascierto, Luis Matamala, Eric Gutierrez, Piotr Rutkowski, Helen Gogas, Christopher D. Lao, J. Menezes, Stéphane Dalle, Ana Arance, Jean‐Jacques Grob, Laurence Toms, K Jonczak, A.M. Sobiesk, Georgina V. Long

    Cyhoeddwyd 2021
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  16. 16
    A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy

    A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-... gan Sarah A. Weiss, Mario Sznol, Montaser Shaheen, Miguel‐Ángel Berciano‐Guerrero, Eva Muñoz‐Couselo, Delvys Rodríguez‐Abreu, Valentina Boni, Lynn M. Schuchter, María González‐Cao, Ana Arance, Wei Wei, Apar Kishor Ganti, Ralph J. Hauke, Alfonso Berrocal, Nicholas Iannotti, Frank J. Hsu, Harriet M. Kluger

    Cyhoeddwyd 2023
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  17. 17
    Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial

    Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial gan Michael A. Davies, Philippe Saïag, Caroline Robert, Jean‐Jacques Grob, Keith T. Flaherty, Ana Arance, Vanna Chiarion‐Sileni, L. Thomas, Thierry Lesimple, Laurent Mortier, Stergios J. Moschos, David Hogg, Iván Márquez‐Rodas, Michele Del Vecchio, Célèste Lebbé, Nicolás Meyer, Ying Zhang, Yingjie Huang, Bijoyesh Mookerjee, Georgina V. Long

    Cyhoeddwyd 2017
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  18. 18
    Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

    Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study gan Caroline Robert, Antoni Ribas, Jacob Schachter, Ana Arance, Jean‐Jacques Grob, Laurent Mortier, Adil Daud, Matteo S. Carlino, Catriona M. McNeil, Michal Lotem, James Larkin, Paul Lorigan, Bart Neyns, Christian U. Blank, Teresa M. Petrella, Omid Hamid, Shu-Chih Su, Clemens Krepler, Nageatte Ibrahim, Georgina V. Long

    Cyhoeddwyd 2019
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  19. 19
    Association of <i>BRAF</i> V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma

    Association of <i>BRAF</i> V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma gan Igor Puzanov, Antoni Ribas, Caroline Robert, Jacob Schachter, Marta Nyakas, Adil Daud, Ana Arance, Matteo S. Carlino, Steven O’Day, Georgina V. Long, Kim Margolin, Reinhard Dummer, Dirk Schadendorf, Jose Lutzky, Paolo A. Ascierto, Ahmad A. Tarhini, Jianxin Lin, Robin Mogg, Blanca Homet Moreno, Nageatte Ibrahim, Omid Hamid

    Cyhoeddwyd 2020
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  20. 20
    COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma

    COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma gan Dirk Schadendorf, Reinhard Dummer, Keith T Flaherty, Caroline Robert, Ana Arance, Jan Willem B. de Groot, Claus Garbe, Helen J Gogas, Ralf Gutzmer, Ivana Krajsová, Gabriella Liszkay, Carmen Loquai, Mario Mandalà, Naoya Yamazaki, Paola Queirolo, Carolin Guenzel, Anna Polli, Mahgull Thakur, Alessandra di Pietro, Paolo A Ascierto

    Cyhoeddwyd 2024
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:

Offerynnau Chwilio: